A systems analysis of the chemosensitivity of breast cancer cells to the polyamine analogue PG-11047

BMC Medicine

Volumn 7, Issue , 2009, Pages

  Kuo, Wen Lin ^a   Das, Debopriya ^a   Ziyad, Safiyyah ^a   Bhattacharya, Sanchita ^a   Gibb, William J ^a   Heiser, Laura M ^a   Sadanandam, Anguraj ^a   Fontenay, Gerald V ^a   Hu, Zhi ^b   Wang, Nicholas J ^a   Bayani, Nora ^a   Feiler, Heidi S ^a   Neve, Richard M ^a   Wyrobek, Andrew J ^a   Spellman, Paul T ^a   Marton, Laurence J ^c   Gray, Joe W ^a,b  

^a LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Progen Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; INTERFERON; PG 11047; POLYAMINE DERIVATIVE; UNCLASSIFIED DRUG; (N(1),N(12))BIS(ETHYL) 6,7 DEHYDROSPERMINE; (N(1),N(12))BIS(ETHYL)-6,7-DEHYDROSPERMINE; DRUG DERIVATIVE; SPERMINE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL CYCLE PHASE; CELL FUNCTION; CHEMOSENSITIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; DRUG RESPONSE; DRUG SENSITIVITY; GENE IDENTIFICATION; GENETIC MARKER; GENETIC TRANSCRIPTION; GROWTH INHIBITION; HUMAN; HUMAN CELL; PREDICTION; PROTEOMICS; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION; SYSTEM ANALYSIS; BREAST TUMOR; CELL CYCLE; CELL PROLIFERATION; DRUG EFFECT; FEMALE; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; HUMANS; SPERMINE;

EID: 74049148166     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/1741-7015-7-77     Document Type: Article

References (52)

1. Cohen SS. A Guide to the Polyamines. 1998, New York: Oxford University Press.
2. Casero RA, Marton LJ. Targeting polyamine metabolism and function in cancer and other hyperproliferative diseases. Nat Rev Drug Discov 2007, 6(5):373-390. 10.1038/nrd2243, 17464296.
3. Saunders LR, Verdin E. Ornithine decarboxylase activity in tumour cell lines correlates with sensitivity to cell death induced by histone deacetylase inhibitors. Mol Cancer Ther 2006, 5(11):2777-2785. 10.1158/1535-7163.MCT-06-0298, 17121924.
4. Levin VA, Hess KR, Choucair A, Flynn PJ, Jaeckle KA, Kyritsis AP, Yung WK, Prados MD, Bruner JM, Ictech S, et al. Phase III randomized study of postradiotherapy chemotherapy with combination alpha-difluoromethylornithine-PCV versus PCV for anaplastic gliomas. Clin Cancer Res 2003, 9(3):981-990.
5. Meyskens FL, McLaren CE, Pelot D, Fujikawa-Brooks S, Carpenter PM, Hawk E, Kelloff G, Lawson MJ, Kidao J, McCracken J, et al. Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prev Res Phila Pa 2008, 1(1):32-38. 10.1158/1940-6207.CAPR-08-0042, 2562024, 18841250.
6. Casero RA, Woster PM. Recent advances in the development of polyamine analogues as antitumour agents. J Med Chem 2009, 52(15):4551-4573. 10.1021/jm900187v, 19534534.
7. Reddy VK, Valasinas A, Sarkar A, Basu HS, Marton LJ, Frydman B. Conformationally restricted analogues of 1N,12N-bisethylspermine: synthesis and growth inhibitory effects on human tumor cell lines. J Med Chem 1998, 41(24):4723-4732. 10.1021/jm980172v, 9822543.
8. Hacker A, Marton LJ, Sobolewski M, Casero RA. In vitro and in vivo effects of the conformationally restricted polyamine analogue CGC-11047 on small cell and non-small cell lung cancer cells. Cancer Chemother Pharmacol 2008, 63(1):45-53. 10.1007/s00280-008-0706-x, 18301893.
9. Perou CM, Sørlie T, Eisen MB, Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al. Molecular portraits of human breast tumors. Nature 2000, 406(6797):747-752. 10.1038/35021093, 10963602.
10. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003, 100(14):8418-8423. 10.1073/pnas.0932692100, 166244, 12829800.
11. Chin K, DeVries S, Fridlyand J, Spellman PT, Roydasgupta R, Kuo WL, Lapuk A, Neve RM, Qian Z, Ryder T, et al. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 2006, 10(6):529-541. 10.1016/j.ccr.2006.10.009, 17157792.
12. Davidson NE, Hahm HA, McCloskey DE, Woster PM, Casero RA. Clinical aspects of cell death in breast cancer: the polyamine pathway as a new target for treatment. Endocr Relat Cancer 1999, 6(1):69-73. 10.1677/erc.0.0060069, 10732790.
13. Holst CM, Frydman B, Marton LJ, Oredsson SM. Differential polyamine analogue effects in four human breast cancer cell lines. Toxicology 2006, 223(1-2):71-81. 10.1016/j.tox.2006.03.009, 16697514.
14. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006, 10(6):515-527. 10.1016/j.ccr.2006.10.008, 2730521, 17157791.
15. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004, 10(16):5367-5374. 10.1158/1078-0432.CCR-04-0220, 15328174.
16. Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, Perou CM, Nielsen TO. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 2008, 14(5):1368-1376. 10.1158/1078-0432.CCR-07-1658, 18316557.
17. Hennessy BT, Gonzalez-Angulo AM, Stemke-Hale K, Gilcrease MZ, Krishnamurthy S, Lee JS, Fridlyand J, Sahin A, Agarwal R, Joy C, et al. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res 2009, 69(10):4116-4124. 10.1158/0008-5472.CAN-08-3441, 19435916.
18. . NCI/NIH Developmental Therapeutic Program, Human Tumour Cell Line Screen NCI/NIH Developmental Therapeutic Program, Human Tumour Cell Line Screen., http://dtp.nci.nih.gov/branches/btb/ivclsp.html
19. Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, Vistica D, Hose C, Langley J, Cronise P, Vaigro-Wolff A, et al. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst 1991, 83(11):757-766. 10.1093/jnci/83.11.757, 2041050.
20. Dolbeare F, Gratzner H, Pallavicini MG, Gray JW. Flow cytometric measurement of total DNA content and incorporated bromodeoxyuridine. Proc Natl Acad Sci USA 1983, 80(18):5573-5577. 10.1073/pnas.80.18.5573, 384300, 6577444.
21. Das D, Nahle Z, Zhang MQ. Adaptively inferring human transcriptional subnetworks. Molecular systems biology 2006, 2:2006-0029. 10.1038/msb4100067, 1681499, 16760900.
22. Storey JD, Tibshirani R. Statistical significance for genomewide studies. Proceedings of the National Academy of Sciences of the United States of America 2003, 100(16):9440-9445. 10.1073/pnas.1530509100, 170937, 12883005.
23. Hess KR, Anderson K, Symmans WF, Valero V, Ibrahim N, Mejia JA, Booser D, Theriault RL, Buzdar AU, Dempsey PJ, et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin and cyclophosphamide in breast cancer. J Clin Oncol 2006, 24(26):4236-4244. 10.1200/JCO.2006.05.6861, 16896004.
24. Ignatenko NA, Yerushalmi HF, Pandey R, Kachel KL, Stringer DE, Marton LJ, Gerner EW. Gene expression analysis of HCT116 colon tumour-derived cells treated with the polyamine analog PG-11047. Cancer Genomics Proteomics 2009, 6(3):161-175.
25. Myhre L, Alm K, Hegardt C, Staaf J, Jönsson G, Larsson S, Oredsson SM. Different cell cycle kinetic effects of N1, N11-diethylnorspermine-induced polyamine depletion in four human breast cancer cell lines. Anticancer Drugs 2008, 19(4):359-368. 10.1097/CAD.0b013e3282f7f518, 18454046.
26. Satriano J, Ishizuka S, Archer DC, Blantz RC, Kelly CJ. Regulation of intracellular polyamine biosynthesis and transport by NO and cytokines TNF-alpha and IFN-gamma. Am J Physiol 1999, 276:C892-899.
27. Macrae M, Neve RM, Rodriguez-Viciana P, Haqq C, Yeh J, Chen C, Gray JW, McCormick F. A conditional feedback loop regulates Ras activity through EphA2. Cancer Cell 2005, 8(2):111-118. 10.1016/j.ccr.2005.07.005, 16098464.
28. Palacios J, Robles-Frias MJ, Castilla MA, Lopez-Garcia MA, Benftez J. The molecular pathology of herediatary breast cancer. Pathobiology 2008, 75(2):85-94. 10.1159/000123846, 18544963.
29. Lu S, Simin K, Khan A, Mercurio AM. Analysis of integrin beta4 expression in human breast cancer: association with basal-like tumors and prognostic soignificance. Clin Cancer Res 2008, 14(4):1050-1058. 10.1158/1078-0432.CCR-07-4116, 18281537.
30. Yano M, Hirai K, Naito Z, Yokoyama M, Ishiwata T, Shiraki Y, Inokuchi M, Asano G. Expression of cathepsin B and cystatin C in human breast cancer. Surg Today 2001, 31(5):385-389. 10.1007/s005950170126, 11381499.
31. Padau D, Massague J. Roles of TGFbeta in metastasis. Cell Res 2009, 19(1):89-102. 10.1038/cr.2008.316, 19050696.
32. Martin TA, Pereira G, Watkins G, Mansel RE, Jiang WG. N-WASP is a putative tumour suppressor in breast cancer cells, in vitro and in vivo and is associated with clinical outcome in patients with breast cancer. Clin Exp Metastasis 2008, 25(2):97-108. 10.1007/s10585-007-9120-8, 17985201.
33. Jiang WG, Raz A, Douglas-Jones A, Mansel RE. Expression of autocrine motility factor (AMF) and its receptor, AMFR, in human breast cancer. J Histochem Cytochem 2006, 54(2):231-241. 10.1369/jhc.5A6785.2005, 16204225.
34. Prehoda KE, Scott JA, Mullins RD, Lim WA. Integration of multiple signals through cooperative regulation of the N-WASP-Arp2/3 complex. Science 2000, 290(5492):801-806. 10.1126/science.290.5492.801, 11052943.
35. Kariya Y, Miyazaki K. The basement membrane protein laminin-5 acts as a soluble cell motility factor. Exp Cell Res 2004, 297:508-520. 10.1016/j.yexcr.2004.03.044, 15212952.
36. Kojic LD, Joshi B, Lajoie P, Le PU, Cox ME, Turbin DA, Wiseman SM, Nabi IRWH, Raz A. Raft-dependent endocytosis of autocrine motility factor is phosphatidylinositol 3-kinase-dependent in breast carcinoma cells. J Biol Chem 2007, 282(40):29305-29313. 10.1074/jbc.M704069200, 17690101.
37. McCormack SA, Johnson LR. Polyamines and cell migration. J Physiol Pharmacol 2001, 52(3):327-349.
38. Carpenter PM, Wang-Rodriguez J, Chan OT, Wilczynski SP. Laminin 5 expression in metaplastic breast carcinomas. Am J Surg Pathol 2008, 32(3):345-353. 10.1097/PAS.0b013e3181592201, 18300817.
39. Song IS, Tatebe S, Dai W, Kuo MT. Delayed mechanism for induction of gamma-glutamylcysteine synthetase heavy subunit mRNA stability by oxidative stress involving p38 mitogen-activated protein kinase signaling. J Biol Chem 2005, 280(31):28230-28240. 10.1074/jbc.M413103200, 15946948.
40. Li Y, Keller DM, Scott JD, Lu H. CK2 phosphorylates SSRP1 and inhibits its DNA-binding activity. J Biol Chem 2005, 280(12):11869-11875. 10.1074/jbc.M413944200, 15659405.
41. Horowitz DS, Lee EJ, Mabon SA, Misteli T. A cyclophilin functions in pre-mRNA splicing. EMBO J 2002, 21(3):470-480. 10.1093/emboj/21.3.470, 125845, 11823439.
42. Reinberg D, Sims RJ. de FACTo nucleosome dynamics. J Biol Chem 2006, 281(33):23297-23301. 10.1074/jbc.R600007200, 16766522.
43. Stegmeier F, Sowa ME, Nalepa G, Gygi SP, Harper JW, Elledge SJ. The tumour suppressor CYLD regulates entry into mitosis. Proc Natl Acad Sci USA 2007, 104(21):8869-8874. 10.1073/pnas.0703268104, 1867381,1867381, 17495026.
44. Eto M, Elliott E, Prickett TD, Brautigan DL. Inhibitor-2 regulates protein phosphatase-1 complexed with NimA-related kinase to induce centrosome separation. J Biol Chem 2002, 277(46):44013-44020. 10.1074/jbc.M208035200, 12221103.
45. Kovalenko A, Chable-Bessia C, Cantarella G, Israël A, Wallach D, Courtois G. The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination. Nature 2003, 424(6950):801-805. 10.1038/nature01802, 12917691.
46. Monaco C, Negrini M, Sozzi G, Veronese ML, Vorechovsky I, Godwin AK, Croce CM. Molecular cloning and characterization of LOH11CR2A, a new gene within a refined minimal region of LOH at 11q23. Genomics 1997, 46(2):217-222. 10.1006/geno.1997.5036, 9417908.
47. Antón IM, Jones GE, Wandosell F, Geha R, Ramesh N. WASP-interacting protein (WIP): working in polymerisation and much more. Trends Cell Biol 2007, 17(11):555-562. 10.1016/j.tcb.2007.08.005, 17949983.
48. Sathyanarayana UG, Padar A, Huang CX, Suzuki M, Shigematsu H, Bekele BN, Gazdar AF. Aberrant promoter methylation and silencing of laminin-5-encoding genes in breast carcinoma. Clin Cancer Res 2003, 9(17):6389-6394.
49. Fiaschi T, Marzella R, Veggi D, Marzocchini R, Raugei G, Rocchi M, Ramponi G. Assignment of the human erythrocyte acylphosphatase gene (ACYP1) to chromosome band 14q24.3. Cytogenet Cell Genet 1998, 81:235-236. 10.1159/000015037, 9730610.
50. Barker HE, Smyth GK, Wettenhall J, Ward TA, Bath ML, Lindeman GJ, Visvader JE. Deaf-1 regulates epithelial cell proliferation and side-branching in the mammary gland. BMC Dev Biol 2008, 8:94-107. 10.1186/1471-213X-8-94, 2570686, 18826651.
51. Manne U, Gary BD, Oelschlager DK, Weiss HL, Frost AR, Grizzle WE. Altered subcellular localization of suppressin, a novel inhibitor of cell-cycle entry, is an independent prognostic factor in colorectal adenocarcinomas. Clin Cancer Res 2001, 7(11):3495-3503.
52. Yao H, Ye J. Long chain acyl-CoA synthetase 3-mediated phosphatidylcholine synthesis is required for assembly of very low density lipoproteins in human hepatoma Huh7 cells. J Biol Chem 2008, 283(2):849-854. 10.1074/jbc.M706160200, 18003621.